Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, ADMA Biologics, Inc. (ADMA) has a Wall Street consensus price target of $16.00, based on estimates from 9 covering analysts. With the stock currently trading at $15.57, this represents a potential upside of +2.8%. The company has a market capitalization of $3.71B.
Analyst price targets range from a low of $14.00 to a high of $18.00, representing a 25% spread in expectations. The median target of $16.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ADMA trades at a trailing P/E of 19.2x and forward P/E of 16.3x. Analysts expect EPS to grow +11.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $34.94, with bear and bull scenarios of $-200.53 and $19.32 respectively. Model confidence stands at 45/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ADMA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for ADMA is $16, close to the current price of $15.57 (2.8% implied move). Based on 9 analyst estimates, the stock appears fairly valued near current levels.
ADMA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $16 implies 2.8% upside from current levels.
With a forward P/E of 16.3037x, ADMA trades at a relatively low valuation. The consensus target of $16 implies 2.8% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $18 for ADMA, while the most conservative target is $14. The consensus of $16 represents the median expectation. Our quantitative valuation model projects a bull case target of $19 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ADMA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ADMA stock forecast based on 9 Wall Street analysts shows a consensus price target of $16, with estimates ranging from $14 (bear case) to $18 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $35, with bear/bull scenarios of $-201/$19.
Our quantitative valuation model calculates ADMA's fair value at $35 (base case), with a bear case of $-201 and bull case of $19. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 45/100.
ADMA trades at a forward P/E ratio of 16.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
ADMA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $16 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ADMA analyst price targets range from $14 to $18, a 25% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $16 consensus represents the middle ground. Our model's $-201-$19 range provides an independent fundamental perspective.